ODAIA, a Canadian startup that specializes in developing MAPTUAL, an AI-powered commercial insights SaaS platform for pharmaceutical companies, has successfully raised $25 million in Series B funding. The funding round was co-led by Threshold Ventures and Monograph Capital, with participation from Wittington Ventures and existing investors Flint Capital, BDC Capital’s Women in Technology Venture Fund, StandUp Ventures, and Graphite Ventures.
Through this funding, ODAIA hopes to expand its business and support the growth of its AI-powered solutions, as the company's mission is to help pharmaceutical companies make life-changing therapies more accessible to patients. It is important to Philip Poulidis, CEO and Co-Founder of ODAIA, that investors recognize the significant problem the company solves for the pharmaceutical industry. In order to provide its clients with the predictive tools they need for today's and tomorrow's market, ODAIA is continuing to enhance its product and build its team with these funds.
ODAIA's lead product, MAPTUAL, is a SaaS platform that uses AI to automate the prospecting, qualifying, and engagement of healthcare providers (HCP), which has traditionally been a manual and time-consuming process. MAPTUAL empowers leading life science brands by providing a near real-time and predictive perspective on the dynamic changes of the pharmaceutical marketplace, enabling more efficient delivery of therapeutics, drugs, and vaccines to the markets that need them.
As part of the funding round, Emily Melton, managing partner of Threshold Ventures, and Charles Conn, co-founder and partner of Monograph Ventures, will join ODAIA's board, and Megan Kelly, principal of Threshold Ventures, will join as a board observer. This funding will allow ODAIA to continue revolutionizing pharmaceutical marketing and commercialization with its AI-powered solutions, ultimately helping patients receive life-changing therapies faster.
